Abrogation of Bronchial Eosinophilic Inflammation and Attenuated Eotaxin Content in Protease-Activated Receptor 2-Deficient Mice

スポンサーリンク

概要

• 論文の詳細を見る

• Protease-activated receptor 2 (PAR2) belongs to the PAR family (PAR1 to PAR4), which is activated by serine proteases (trypsin, tryptase, etc.). In this study, we evaluated the role of PAR2 in allergic inflammation of airways using PAR2-deficient (PAR2−/−) mice. In wild- type mice, infiltration of eosinophils and high eotaxin content were found in bronchoalveolar lavage fluid (BALF) after ovalbumin (OA) sensitization and following challenge. In contrast, both OA-induced infiltration of eosinophils and increase of eotaxin content were abrogated in BALF from PAR2−/− mice. The activation of PAR2 might be essential in the production of eotaxin and consequential allergic inflammation in airways.

• 社団法人 日本薬理学会の論文
• 2005-05-20

著者

• Takizawa Toshiaki

  Tokyo New Drug Research Laboratories Ii Pharmaceutical Division Kowa Company Ltd.

• Takizawa Toshiaki

  興和

• Takizawa Toshiaki

  岐阜薬科大学 薬理

• KANKE Toru

  Tokyo New Drug Research Laboratories, Kowa Company Limited

• TAMIYA Masaki

  Tokyo New Drug Research Laboratories II, Pharmaceutical Division, Kowa Company Ltd.

• HARA Takuya

  Tokyo New Drug Research Laboratories II, Pharmaceutical Division, Kowa Company Ltd.

• MATSUMOTO Jiro

  Tokyo New Drug Research Laboratories II, Pharmaceutical Division, Kowa Company Ltd.

• SAITO Naohiro

  Tokyo New Drug Research Laboratories II, Pharmaceutical Division, Kowa Company Ltd.

• KAWAGOE Junichi

  Tokyo New Drug Research Laboratories II, Pharmaceutical Division, Kowa Company Ltd.

• HATTORI Yukio

  Tokyo New Drug Research Laboratories II, Pharmaceutical Division, Kowa Company Ltd.

• Kanke Toru

  興和

• Kanke Toru

  Tokyo New Drug Research Laboratories Ii Pharmaceutical Division Kowa Company Ltd.

• Matsumoto Jiro

  Tokyo New Drug Research Laboratories Ii Pharmaceutical Division Kowa Company Ltd.

• Kawagoe Junichi

  Tokyo New Drug Research Laboratories Ii Pharmaceutical Division Kowa Company Ltd.

• Kawagoe Junichi

  興和東京研究所

• Tamiya M

  Tokyo New Drug Research Laboratories Ii Pharmaceutical Division Kowa Company Ltd.

• Tamiya Masaki

  興和東京研究所

• Saito Naohiro

  Tokyo New Drug Research Laboratories Ii Pharmaceutical Division Kowa Company Ltd.

• Saito Naohiro

  興和東京研究所

• Hara Takuya

  Tokyo New Drug Research Laboratories Ii Pharmaceutical Division Kowa Company Ltd.

• Tamiya Masaki

  Tokyo New Drug Research Laboratories Ii Pharmaceutical Division Kowa Company Ltd.

• Hattori Yukio

  Tokyo New Drug Research Laboratories Ii Pharmaceutical Division Kowa Company Ltd.

関連論文

• Role of mast cells in antigen-induced airway inflammation and bronchial hyperresponsiveness in rats.
• Effects of a New Antiallergic Drug, VUF-K-8788, on Infiltration of Lung Parenchyma by Eosinophils in Guinea Pigs and Eosinophil-Adhesion to Human Umbilical Vein Endothelial Cells(HUVEC)
• Physiology and Pathophysiology of Proteinase-Activated Receptors (PARs) : PAR-2 as a Potential Therapeutic Target
• Abrogation of Bronchial Eosinophilic Inflammation and Attenuated Eotaxin Content in Protease-Activated Receptor 2-Deficient Mice
• VUF-K-8788,a periphery-selective histamine H1 antagonist with anti-pruritic activities.
• Effect of Antiallergic Drugs on Interleukin 5-Induced Eosinophil Infiltration of Rat Airways
• Effect of Protease-Activated Receptor-2 Deficiency on Allergic Dermatitis in the Mouse Ear
• VUF-K-8788, a Periphery-Selective Histamine H_1 Antagonist With Anti-pruritic Activities
• Effects of a New Antiallergic Agent, VUF-K-8788,on Experimental Asthmatic Reactions in Guinea Pigs.
• Role of Mast Cells in Antigen-Induced Airway Inflammation and Bronchial Hyperresponsiveness in Rats
• Defect of Delta-Sarcoglycan Gene Is Responsible for Development of Dilated Cardiomyopathy of a Novel Hamster Strain, J2N-k : Calcineurin/PP2B Activity in the Heart of J2N-k Hamster
• Effects of Salt-loading on the Onset of Stroke and the Development of Cerebral Lesions in SHRSP
• Venous Distensibility in Stroke-Prone SHR at 6 and 15 Weeks of Age---Comparison with Age-Matched WKY---
• Possibility of the Low Defensive Fibrinolysis in SHRSP
• Effects of beta-blockers upon the blood pressure, mortality and cerebral injury in the salt-loaded SHRSP
• The Blood Pressure, Life Span, Body Weight in Both Sexes of SHRSP during 55 Weeks under Specific Pathogen Free System
• The Heart Failure and Myocardial Changes of SHRSP derived from Non-stroke Parents under Specific Pathogen-free System
• Ultrastructural Changes of the Myocardium of SHRSP derived from the parents of Cardiac Death under Specific Pathogen-Free System

もっと見る 閉じる

スポンサーリンク